Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Head and Neck Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 64 articles: HTML format

Single Articles

November 2025
1. PAN KF, Chou HL, Wang WL, Chen BR, et al
   KSRP-mediated Wnt/beta-catenin activation promotes follicular thyroid cancer progression and stemness.
   Br J Cancer. 2025;133:1111-1121.
   PubMed     Abstract available
   
   
   October 2025
2. DU Y, Feng R, Chang ET, Yin L, et al
   Population-based nasopharyngeal carcinoma survival in southern China.
   Br J Cancer. 2025 Oct 29. doi: 10.1038/s41416-025-03232.
   PubMed     Abstract available
   
   
   
3. KAUR R, Chauhan A, Saini KK, Datta A, et al
   Cornulin, a potential prognostic biomarker in head and neck squamous cell carcinoma, acts as an anti-tumour agent by inhibiting cell cycle through upregulation of p18.
   Br J Cancer. 2025 Oct 27. doi: 10.1038/s41416-025-03222.
   PubMed     Abstract available
   
   
   
4. WU WZ, Huang HC, Zhu GH, Liao LD, et al
   Serum multiomics prediction of prognosis and adverse reactions to concurrent chemoradiotherapy in patients with esophageal cancer.
   Br J Cancer. 2025 Oct 8. doi: 10.1038/s41416-025-03229.
   PubMed     Abstract available
   
   
   
5. CUI K, Hu S, Zha Y, Ding K, et al
   Correction: CD49a(+) NK cells promote esophageal cancer development by inducing MDSCs infiltration via GM-CSF.
   Br J Cancer. 2025 Oct 6. doi: 10.1038/s41416-025-03220.
   PubMed    
   
   
   
6. YADOLLAHI P, McCord KA, Li Y, Dayoub H, et al
   Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting.
   Br J Cancer. 2025 Oct 6. doi: 10.1038/s41416-025-03189.
   PubMed     Abstract available
   
   
   
7. PATIL N, Lal Z, Sridhar T, Pareek M, et al
   A call for action: closing the gap on ethnic disparities in oral cavity cancer care.
   Br J Cancer. 2025;133:917-918.
   PubMed     Abstract available
   
   
   September 2025
8. WU KP, Luo XQ, Li QQ, Yang HC, et al
   Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
   Br J Cancer. 2025 Sep 5. doi: 10.1038/s41416-025-03169.
   PubMed     Abstract available
   
   
   
9. LI Y, Yuan X, Yin XF, Zheng D, et al
   Proteomics analysis and immune profiling reveal regulators of PD-L1 in oesophageal squamous cell carcinoma.
   Br J Cancer. 2025;133:448-463.
   PubMed     Abstract available
   
   
   
10. WALKER RC, Breininger SP, Sharpe BP, Harrington J, et al
    Cancer-associated fibroblasts are associated with neo-adjuvant treatment response in oesophageal adenocarcinoma.
    Br J Cancer. 2025;133:633-647.
    PubMed     Abstract available
    
    
    
11. SPENDER LC, Watt DM, Baxter MA, Shuttleworth MK, et al
    AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma.
    Br J Cancer. 2025;133:709-722.
    PubMed     Abstract available
    
    
    August 2025
12. LAN K, Li S, Jia G, Li S, et al
    Correction: Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.
    Br J Cancer. 2025 Aug 27. doi: 10.1038/s41416-025-03077.
    PubMed    
    
    
    
13. KO JM, Guo C, Leung AK, Chan SC, et al
    Oncogenic NFE2L2 mutations in plasma ctDNA and tumors are predictors and prognosticators of chemoradiation therapy in resectable esophageal squamous cell carcinoma.
    Br J Cancer. 2025 Aug 8. doi: 10.1038/s41416-025-03113.
    PubMed     Abstract available
    
    
    July 2025
14. FAN C, Liu F, He C, Liu J, et al
    Radiotherapy combined with anlotinib in locoregional recurrent esophageal squamous cell carcinoma after radical surgery: a prospective, Phase II clinical trial.
    Br J Cancer. 2025 Jul 16. doi: 10.1038/s41416-025-03101.
    PubMed     Abstract available
    
    
    
15. ADACHI K, Yamashita K, Kamakura Y, Momose K, et al
    High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.
    Br J Cancer. 2025 Jul 15. doi: 10.1038/s41416-025-03087.
    PubMed     Abstract available
    
    
    June 2025
16. VAN HEUSDEN HC, van Beers MA, Schaeffers AWMA, Swartz E, et al
    The predictive and prognostic role of radiologically defined sarcopenia in head and neck cancer: a systematic review and multi-level meta-analysis.
    Br J Cancer. 2025 Jun 2. doi: 10.1038/s41416-025-03049.
    PubMed     Abstract available
    
    
    
17. TRAN TV, O'Brien KM, Troisi R, Sandler DP, et al
    In-utero and newborn factors and thyroid cancer incidence in adult women in the Sister Study cohort.
    Br J Cancer. 2025;132:1056-1063.
    PubMed     Abstract available
    
    
    
18. DE OLIVEIRA THA, Anderson LA, Craig SG, Coleman HG, et al
    Infectious agents and progression from Barrett's oesophagus to oesophageal adenocarcinoma: a nested case-control study.
    Br J Cancer. 2025;132:1050-1055.
    PubMed     Abstract available
    
    
    May 2025
19. CUI K, Hu S, Zha Y, Ding K, et al
    CD49a(+) NK cells promote esophageal cancer development by inducing MDCSs infiltration via GM-CSF.
    Br J Cancer. 2025 May 28. doi: 10.1038/s41416-025-03065.
    PubMed     Abstract available
    
    
    
20. PAPANIKOLAOU C, Economopoulou P, Spathis A, Kotsantis I, et al
    Association of DNA damage response signals and oxidative stress status with nivolumab efficacy in patients with Head and Neck Squamous Cell Carcinoma.
    Br J Cancer. 2025 May 23. doi: 10.1038/s41416-025-03032.
    PubMed     Abstract available
    
    
    
21. FEI-ZHANG DJ, Cuenca CM, Haskins AD, Stein AP, et al
    Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US.
    Br J Cancer. 2025 May 15. doi: 10.1038/s41416-025-03056.
    PubMed     Abstract available
    
    
    
22. LAN K, Li S, Jia G, Li S, et al
    Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.
    Br J Cancer. 2025 May 12. doi: 10.1038/s41416-025-03044.
    PubMed     Abstract available
    
    
    
23. CHENG H, Chen J, Li Y, Li Y, et al
    Determining the optimal duration of oral adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Br J Cancer. 2025 May 6. doi: 10.1038/s41416-025-03033.
    PubMed     Abstract available
    
    
    
24. HUBER D, Kors TA, Schutt L, Hofmann L, et al
    The role of plasma-derived small extracellular vesicles in pre-metastatic niche formation through modulation of macrophages in head and neck squamous cell carcinoma.
    Br J Cancer. 2025 May 5. doi: 10.1038/s41416-025-03001.
    PubMed     Abstract available
    
    
    April 2025
25. INOUE-CHOI M, Ramirez Y, O'Connell C, Berrington de Gonzalez A, et al
    Hot beverage intake and oesophageal cancer in the UK Biobank: prospective cohort study.
    Br J Cancer. 2025;132:652-659.
    PubMed     Abstract available
    
    
    
26. HUANG G, Chen S, Han B, Zhang G, et al
    Apolipoprotein D is crucial for promoting perineural invasion in salivary adenoid cystic carcinoma.
    Br J Cancer. 2025;132:599-610.
    PubMed     Abstract available
    
    
    March 2025
27. LU X, Lin W, Zheng J, Huang W, et al
    Sodium nitrite orchestrates macrophage mimicry of tongue squamous carcinoma cells to drive lymphatic metastasis.
    Br J Cancer. 2025;132:340-353.
    PubMed     Abstract available
    
    
    February 2025
28. SHEPHARD AJ, Mahmood H, Raza SEA, Khurram SA, et al
    A novel AI-based score for assessing the prognostic value of intra-epithelial lymphocytes in oral epithelial dysplasia.
    Br J Cancer. 2025;132:168-179.
    PubMed     Abstract available
    
    
    
29. STOGBAUER F, Wirth M, Lauterbach M, Wollenberg B, et al
    Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas.
    Br J Cancer. 2025;132:212-221.
    PubMed     Abstract available
    
    
    
30. BARGHOUT SH, Meti N, Chotai S, Kim CJH, et al
    Adaptive Universal Principles for Real-world Observational Studies (AUPROS): an approach to designing real-world observational studies for clinical, epidemiologic, and precision oncology research.
    Br J Cancer. 2025;132:139-153.
    PubMed     Abstract available
    
    
    December 2024
31. LIN J, Orestes MI, Shriver CD, Zhu K, et al
    Post-diagnosis statin use and survival among head and neck cancer patients: a cohort study in a universal health care system.
    Br J Cancer. 2024 Dec 7. doi: 10.1038/s41416-024-02925.
    PubMed     Abstract available
    
    
    November 2024
32. EKSTEDT S, Piersiala K, Kolev A, Farrajota Neves da Silva P, et al
    Phenotypical differences of neutrophils patrolling tumour-draining lymph nodes in head and neck cancer.
    Br J Cancer. 2024 Nov 14. doi: 10.1038/s41416-024-02891.
    PubMed     Abstract available
    
    
    October 2024
33. HOLZMANN KLK, Wolf JL, Stangl S, Lennartz P, et al
    Improved ex vivo fluorescence imaging of human head and neck cancer using the peptide tracer TPP-IRDye800 targeting membrane-bound Hsp70 on tumor cells.
    Br J Cancer. 2024 Oct 15. doi: 10.1038/s41416-024-02872.
    PubMed     Abstract available
    
    
    
34. ZHOU J, Zhao G, Wang S, Li N, et al
    Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review of the last decade.
    Br J Cancer. 2024;131:1021-1031.
    PubMed     Abstract available
    
    
    
35. CHEN YY, Wang PP, Hu Y, Yuan Y, et al
    Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.
    Br J Cancer. 2024;131:1126-1136.
    PubMed     Abstract available
    
    
    September 2024
36. WANG R, Liu S, Chen B, Li Q, et al
    Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study.
    Br J Cancer. 2024;131:709-717.
    PubMed     Abstract available
    
    
    July 2024
37. HARA Y, Baba Y, Oda E, Harada K, et al
    Presence of Fusobacterium nucleatum in relation to patient survival and an acidic environment in oesophagogastric junction and gastric cancers.
    Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02753.
    PubMed     Abstract available
    
    
    
38. LI T, Sun G, Ye H, Song C, et al
    ESCCPred: a machine learning model for diagnostic prediction of early esophageal squamous cell carcinoma using autoantibody profiles.
    Br J Cancer. 2024 Jul 2. doi: 10.1038/s41416-024-02781.
    PubMed     Abstract available
    
    
    May 2024
39. ZHANG D, Jiang D, Jiang L, Ma J, et al
    HLA-A(+) tertiary lymphoid structures with reactivated tumor infiltrating lymphocytes are associated with a positive immunotherapy response in esophageal squamous cell carcinoma.
    Br J Cancer. 2024 May 18. doi: 10.1038/s41416-024-02712.
    PubMed     Abstract available
    
    
    
40. OLIVA M, Heirali A, Watson G, Rooney AM, et al
    Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study.
    Br J Cancer. 2024 May 7. doi: 10.1038/s41416-024-02701.
    PubMed     Abstract available
    
    
    
41. WANG C, Li Y, Wang L, Han Y, et al
    SPP1 represents a therapeutic target that promotes the progression of oesophageal squamous cell carcinoma by driving M2 macrophage infiltration.
    Br J Cancer. 2024;130:1770-1782.
    PubMed     Abstract available
    
    
    
42. WANG Z, Tang S, Cai L, Wang Q, et al
    DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma.
    Br J Cancer. 2024;130:1744-1757.
    PubMed     Abstract available
    
    
    
43. SIJBEN J, Huibertse LJ, Rainey L, Broeders MJM, et al
    Oesophageal cancer awareness and anticipated time to help-seeking: results from a population-based survey.
    Br J Cancer. 2024;130:1795-1802.
    PubMed     Abstract available
    
    
    April 2024
44. MAKOWSKA A, Kontny U, Weiskirchen R
    HeLa cells cross-contaminated nasopharyngeal carcinoma cell lines: Still a common problem.
    Br J Cancer. 2024 Apr 25. doi: 10.1038/s41416-024-02675.
    PubMed    
    
    
    
45. TABATABAEIAN H, Bai Y, Huang R, Chaurasia A, et al
    Navigating therapeutic strategies: HPV classification in head and neck cancer.
    Br J Cancer. 2024 Apr 20. doi: 10.1038/s41416-024-02655.
    PubMed     Abstract available
    
    
    March 2024
46. HIRAI R, Kinugasa H, Yamamoto S, Ako S, et al
    Methylation analysis of DCC gene in saliva samples is an efficient method for non-invasive detection of superficial hypopharyngeal cancer.
    Br J Cancer. 2024 Mar 27. doi: 10.1038/s41416-024-02654.
    PubMed     Abstract available
    
    
    
47. XU J, Chen D, Wu W, Ji X, et al
    A metabolic map and artificial intelligence-aided identification of nasopharyngeal carcinoma via a single-cell Raman platform.
    Br J Cancer. 2024 Mar 7. doi: 10.1038/s41416-024-02637.
    PubMed     Abstract available
    
    
    
48. SHANG Q, Jiang Y, Wan Z, Peng J, et al
    The clinical implication and translational research of OSCC differentiation.
    Br J Cancer. 2024;130:660-670.
    PubMed     Abstract available
    
    
    
49. CHENG Z, Johar A, Nilsson M, Schandl A, et al
    Cancer-related fatigue trajectories up to 5 years after curative treatment for oesophageal cancer.
    Br J Cancer. 2024;130:628-637.
    PubMed     Abstract available
    
    
    February 2024
50. CECCHINI M, Cleary JM, Shyr Y, Chao J, et al
    NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
    Br J Cancer. 2024;130:476-482.
    PubMed     Abstract available
    
    
    
51. JAVED SR, Lord S, El Badri S, Harman R, et al
    CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
    Br J Cancer. 2024;130:467-475.
    PubMed     Abstract available
    
    
    January 2024
52. LIN W, Chen X, Huang Z, Ding Q, et al
    Identification of novel molecular subtypes to improve the classification framework of nasopharyngeal carcinoma.
    Br J Cancer. 2024 Jan 27. doi: 10.1038/s41416-024-02579.
    PubMed     Abstract available
    
    
    
53. LI G, Wang H, Zhong J, Bai Y, et al
    Circulating small extracellular vesicle-based miRNA classifier for follicular thyroid carcinoma: a diagnostic study.
    Br J Cancer. 2024 Jan 18. doi: 10.1038/s41416-024-02575.
    PubMed     Abstract available
    
    
    
54. CHEN Y, Feng Y, Lin Y, Zhou X, et al
    GSTM3 enhances radiosensitivity of nasopharyngeal carcinoma by promoting radiation-induced ferroptosis through USP14/FASN axis and GPX4.
    Br J Cancer. 2024 Jan 16. doi: 10.1038/s41416-024-02574.
    PubMed     Abstract available
    
    
    
55. STOGBAUER F, Beck S, Ourailidis I, Hess J, et al
    Correction: Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer.
    Br J Cancer. 2024 Jan 8. doi: 10.1038/s41416-023-02521.
    PubMed    
    
    
    
56. HUANG Q, Liu Z, Yu Y, Rong Z, et al
    Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test.
    Br J Cancer. 2024 Jan 4. doi: 10.1038/s41416-023-02547.
    PubMed     Abstract available
    
    
    
57. CLEMENTS HA, Underwood TJ, Petty RD
    Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma.
    Br J Cancer. 2024;130:9-18.
    PubMed     Abstract available
    
    
    December 2023
58. ALMANGUSH A, Makitie AA, Leivo I
    Tumour budding in head and neck cancer: what have we learnt and the next steps towards clinical implementation.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02531.
    PubMed    
    
    
    
59. SARODE G, Sarode SC
    Comment on "Development and validation of a multivariable model for prediction of malignant transformation and recurrence of oral epithelial dysplasia".
    Br J Cancer. 2023;129:1875-1876.
    PubMed    
    
    
    November 2023
60. MAHMOOD H, Shephard A, Hankinson P, Bradburn M, et al
    Development and validation of a multivariable model for prediction of malignant transformation and recurrence of oral epithelial dysplasia.
    Br J Cancer. 2023;129:1599-1607.
    PubMed     Abstract available
    
    
    
61. MENG X, Zheng A, Wang J, Wu X, et al
    Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial.
    Br J Cancer. 2023;129:1787-1792.
    PubMed     Abstract available
    
    
    
62. TOWLE R, Dickman CTD, MacLellan SA, Chen J, et al
    Identification of a serum-based microRNA signature that detects recurrent oral squamous cell carcinoma before it is clinically evident.
    Br J Cancer. 2023;129:1810-1817.
    PubMed     Abstract available
    
    
    October 2023
63. LIU JY, Yu ZL, Fu QY, Zhang LZ, et al
    Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80.
    Br J Cancer. 2023;129:925-934.
    PubMed     Abstract available
    
    
    September 2023
64. PAYNE K, Brooks J, Batis N, Khan N, et al
    Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping.
    Br J Cancer. 2023 Sep 21. doi: 10.1038/s41416-023-02428.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.